COVID-19 Clinical Trial
Official title:
Leveraging Community Health Workers to Combat Health Misinformation in Haiti, Malawi, and Rwanda
Verified date | August 2023 |
Source | Harvard Medical School (HMS and HSDM) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Partners In Health (PIH), in collaboration with Harvard Medical School, aims to develop and evaluate an SMS-based intervention for Community Health Workers (CHWs) to combat COVID-19 and mental health-related misinformation in Haiti, Rwanda, and Malawi. The study involves three aims: identifying locally relevant misinformation through a card-sorting exercise with CHWs, developing targeted messages through cognitive interviewing, and evaluating the effectiveness of SMS-based educational message dissemination via a randomized controlled trial. The evaluation will assess the impact on public health practices, knowledge and attitudes among CHWs, and knowledge and attitudes among community members.
Status | Active, not recruiting |
Enrollment | 5100 |
Est. completion date | November 30, 2024 |
Est. primary completion date | August 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | The intervention will be assigned at the unit of the CHWs. These individuals will also be eligible for the CHW longitudinal cohort. Inclusion Criteria: - CHWs affiliated with PIH Rwanda, Malawi, or Haiti - 18+ years of age. Exclusion Criteria: - Less than 18 years old. |
Country | Name | City | State |
---|---|---|---|
Haiti | Zanmi Lasante | Cange | |
Malawi | Partners in Health- Malawi | Neno | |
Rwanda | Partners in Health- Rwanda | Kigali |
Lead Sponsor | Collaborator |
---|---|
Harvard Medical School (HMS and HSDM) | Partners in Health |
Haiti, Malawi, Rwanda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of COVID-19 Vaccines that are Available Monthly at Health Facilities | COVID-19 Vaccine administration will be measured using routinely collected data measured monthly at the health facility level | 24 months | |
Primary | Number of Mental Health Visits/ Consultations Completed Monthly at Health Facilities | Mental health service utilization will be measured using routinely collected data measured monthly at the health facility level | 24 months | |
Primary | Number of Patients who Sought Care from Mental Health Services Monthly at Health Facilities | Mental health service utilization will be measured using routinely collected data measured monthly at the health facility level | 24 months | |
Primary | Number of COVID-19 Vaccine Doses Administered Monthly at Health Facilities | COVID-19 Vaccine administration will be measured using routinely collected data measured monthly at the health facility level | 24 months | |
Secondary | Qualitative Interviews | In-depth qualitative interviews will occur before, during, and after the dissemination of messages. Prior to the message dissemination we will contact between 10-15 randomly selected CHWs per country and provide them with draft messages. Although the content of all messages will be determined by the results of the card sorting exercise, the style of the messages will vary. We will use cognitive interviewing techniques to understand how CHWs interpret each message and ask them to provide their preferences on messaging style. During subsequent qualitative sessions at midline and endline, we will ask up to ten CHWs to provide feedback on the messages that they actually received during the intervention. | Before, after 6 months of the intervention, and after 12 months of the intervention | |
Secondary | Longitudinal Cohort Surveys | In each country, we will also select a random sample of 175 CHWs to participate in in a longitudinal cohort consisting of a quantitative questionnaire administered before, during, and after the intervention. During our survey, we will assess both COVID-19 related outcomes (CHWs' knowledge about COVID-19, vaccination status, and intention to vaccinate) and mental health-related outcomes (CHWs' knowledge about and stigmatization of mental illness). After the start of the intervention, we will also ask CHWs to self-report whether they have received our messages or used our helpline, and we will seek to verify this information by direct observation of text messages or outgoing calls on their phone. | Before, after 6 months of the intervention, and after 12 months of the intervention | |
Secondary | Cross-Sectional Survey | a repeated cross-sectional survey of community members | Before the intervention and after 12 months of the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|